Partner With Us NRI

Gland Pharma Ltd share Price Today

Company details

6M Return 87.18%
1Y Return 1.66%
Mkt Cap.(Cr) 29,040.08
Volume 204,312
Div Yield 0.00%
OI Chg %
Volume 204,312

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Gland Pharma announced Q2FY24 & H1FY24 results:

1. Financial Performance:
- Gland Pharma's Q2FY24 revenue stood at Rs 13,734 million, representing a YoY growth of 32%.
- The company achieved a net profit of Rs 1,941 million during Q2FY24.
- Revenue for H1FY24 was Rs 25,821 million, a 36% increase compared to the previous year.

2. Gross Profit Margin and EBITDA:
- Gland Pharma reported a gross profit margin of 63% in Q2FY24, higher than the previous year.
- The EBITDA margin for the quarter was 23%.
- Cenexi, a subsidiary of Gland Pharma, showed a gross profit margin of 77% despite an operational shutdown.

3. Geographic Revenue Breakdown:
- The USA accounted for 54% of Q2FY24 revenue, down from 65% in the same quarter last year.
- Europe and Rest of the World (ROW) markets saw growth due to the inclusion of Cenexi.
- India contributed to 6% of Q2FY24 revenue.

4. R&D Expenditure:
- Gland Pharma spent Rs 351 million on research and development in Q2FY24.
- The company filed 1 ANDA and received approval for 5 ANDAs during the quarter.

5. Capex:
- Gland Pharma invested a total of Rs 971 million in capital expenditure during Q2FY24.

Commenting on the results, Srinivas Sadu, MD & CEO, Gland Pharma, said, “We ended the first half of FY24 with revenue of Rs 25,821 million, a 36% year-over-year increase, and a net profit of Rs 3,882 million. Pricing and market share trends have shown encouraging indicators of normalization in our key products, contributing to our revenue growth. The overall business stability is restoring confidence, and we stay optimistic about future growth with the forthcoming launches, portfolio expansion, and entry into new markets via a partner-led strategy.

Considering the annual summer shutdown in France & Belgium, revenues at Cenexi are in line with our estimates; However, the gross contribution margins saw a sequential improvement. Cenexi remains a strategic asset with a distinctive acquisition thesis, and we are committed to instituting effective measures and new investments to optimize operations and deliver long-term value to our shareholders.”



Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Gland Pharma Ltd Stocks COMPARISION


Equity Capital: 7,958.72 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,593.44 39,409.91
LAST 3M 57,905.00 19,139.45
LAST 6M 99,888.55 93,017.93
LAST 12M 166,353.23 137,771.51

Gland Pharma Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Gland Pharma Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 67,419.04 crores, it is incorporated in the year 1978. It has reported the consolidated sales of Rs. 1153.90 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 543245 and listed in the National Stock Exchange (NSE) with the code GLAND.

    Glen Pharma Ltd was incorporated as Private Company in Hyderabad. The company is primarily involved in the production of injectable drugs. Gland Pharmaceuticals has a global presence in around 60 countries and operates on a business-to-business model in countries like India, the USA, Canada, Australia, and some European countries. Gland Pharma has a total of seven manufacturing units located in different parts of the country. Gland Pharmaceuticals has 1415 product registrations in multiple countries of the world, with 368 product registrations in the USA and 54 registrations in India. The company has all its
    facilities approved by USFDA and has a track record of receiving no warnings. The promoters within the company currently hold 58.14% of the stake in the company.

    The Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) holds 10.44% and 12.11% of the stake. The balance of 19.32% is by others (retail investors).

    In June 2021, quarterly net sales were Rs. 1,153.90 crores, which has increased by approximately 31% from Rs. 884.21 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 350.68 crores, which has seen a rise by nearly 12% from a net profit of Rs. 313.59 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,137.44 crores, which is also increased by 33% as compared to an operating profit of Rs. 853.76 crores for the quarter ending in June 2020. From Rs. 20.24 in June 2020, the EPS of Gland Pharma Ltd has increased to Rs. 21.41 per share in June 2021. GLAND’s stock closed at Rs. 4131 on 16th August’2021 (NSE) and has returned 86.47% in the last six months and 126.06% in the last year.

Registered Address

Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043

Tel : 91-40-30510999
Email : investors:glandpharma.com
Website : http://www.glandpharma.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543245
Book Closure Date (Month) :
BSE Group : A
ISIN : INE068V01023

FAQ’s on Gland Pharma Ltd Shares

You can buy Gland Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gland Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 07, 2023 03:57 PM the closing price of Gland Pharma Ltd was ₹ 1,763.20.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 07, 2023 03:57 PM, the market cap of Gland Pharma Ltd stood at ₹ 29,040.08.

The latest PE ratio of Gland Pharma Ltd as of Dec 07, 2023 03:57 PM is 39.68

The latest PB ratio of Gland Pharma Ltd as of Dec 07, 2023 03:57 PM is 0.29

The 52-week high of Gland Pharma Ltd is ₹ 1,841.80 while the 52-week low is ₹ 861.00

Download Our App

market app
market app